Chemical ID |
Chemical Name |
Interaction |
Interaction Action |
Publication |
---|
C013123 |
5,10-methylenetetrahydrofolate |
MTHFR protein results in increased metabolism of 5,10-methylenetetrahydrofolate | increases metabolic processing | 16187112
|
C013123 |
5,10-methylenetetrahydrofolate |
MTHFR protein results in increased reduction of 5,10-methylenetetrahydrofolate | increases reduction | 7647779
|
C005984 |
5-methyltetrahydrofolate |
MTHFR protein results in increased chemical synthesis of 5-methyltetrahydrofolate | increases chemical synthesis | 9719624 7647779
|
D006710 |
Homocysteine |
MTHFR protein affects the metabolism of Homocysteine | affects metabolic processing | 20547447
|
D006710 |
Homocysteine |
MTHFR protein mutant form results in increased abundance of Homocysteine | increases abundance | 7647779
|
D006710 |
Homocysteine |
MTHFR protein affects the abundance of Homocysteine metabolite | affects abundance | 19204075
|
D006710 |
Homocysteine |
[MTHFR protein results in increased methylation of Homocysteine] which results in increased chemical synthesis of Methionine | increases chemical synthesis|increases methylation | 18234410
|
D000643 |
Ammonium Chloride |
Ammonium Chloride affects the expression of MTHFR mRNA | affects expression | 16483693
|
D003504 |
Ancitabine |
MTHFR protein affects the susceptibility to Ancitabine | affects response to substance | 18202788
|
D001151 |
Arsenic |
MTHFR gene polymorphism affects the metabolism of and affects the susceptibility to Arsenic | affects metabolic processing|affects response to substance | 17365577 17548696
|
D001151 |
Arsenic |
MTHFR gene polymorphism affects the metabolism of Arsenic | affects metabolic processing | 17637926
|
D001151 |
Arsenic |
MTHFR polymorphism affects the metabolism of Arsenic | affects metabolic processing | 17365577
|
D001151 |
Arsenic |
MTHFR polymorphism affects the methylation of Arsenic | affects methylation | 17440589
|
D003024 |
Clozapine |
MTHFR gene polymorphism affects the susceptibility to Clozapine | affects response to substance | 20547447
|
D003024 |
Clozapine |
MTHFR protein affects the susceptibility to Clozapine | affects response to substance | 20547447
|
D003561 |
Cytarabine |
MTHFR protein affects the susceptibility to Cytarabine | affects response to substance | 18202788
|
D005467 |
Floxuridine |
MTHFR protein affects the susceptibility to Floxuridine | affects response to substance | 18202788
|
D005472 |
Fluorouracil |
MTHFR gene polymorphism affects the susceptibility to Fluorouracil | affects response to substance | 16785472 19203896 17047490 16399440
|
D005472 |
Fluorouracil |
MTHFR gene polymorphism results in increased susceptibility to Fluorouracil | increases response to substance | 15735113 18034621
|
D005472 |
Fluorouracil |
MTHFR gene polymorphism results in increased susceptibility to [Fluorouracil co-treated with Leucovorin] | affects cotreatment|increases response to substance | 18633250
|
D005472 |
Fluorouracil |
MTHFR protein affects the susceptibility to Fluorouracil | affects response to substance | 15735113 18034621
|
D005472 |
Fluorouracil |
MTHFR protein affects the susceptibility to Fluorouracil analog | affects response to substance | 15608557
|
D005472 |
Fluorouracil |
MTHFR protein results in increased metabolism of Fluorouracil | increases metabolic processing | 18034621
|
D005492 |
Folic Acid |
Folic Acid affects the expression of MTHFR mRNA | affects expression | 17311948
|
D005492 |
Folic Acid |
[Folic Acid co-treated with MTHFR gene SNP] affects the methylation of MGMT promoter | affects cotreatment|affects methylation | 17301267
|
D005492 |
Folic Acid |
Folic Acid inhibits the reaction [MTHFR gene polymorphism results in increased activity of ACHE protein] | decreases reaction|increases activity | 16375580
|
D005492 |
Folic Acid |
MTHFR gene mutant form results in decreased abundance of Folic Acid | decreases abundance | 17115185
|
D005492 |
Folic Acid |
MTHFR gene polymorphism affects the abundance of Folic Acid | affects abundance | 16690736 16621645
|
D005492 |
Folic Acid |
MTHFR gene polymorphism affects the reaction [Folic Acid affects the methylation of CDKN2A promoter] | affects methylation|affects reaction | 16646054
|
D005492 |
Folic Acid |
MTHFR protein affects the metabolism of Folic Acid | affects metabolic processing | 20547447
|
D002955 |
Leucovorin |
MTHFR gene polymorphism results in increased susceptibility to [Fluorouracil co-treated with Leucovorin] | affects cotreatment|increases response to substance | 18633250
|
D008715 |
Methionine |
[MTHFR protein results in increased methylation of Homocysteine] which results in increased chemical synthesis of Methionine | increases chemical synthesis|increases methylation | 18234410
|
D008727 |
Methotrexate |
MTHFR gene SNP affects the susceptibility to Methotrexate | affects response to substance | 17488658
|
C076029 |
olanzapine |
MTHFR gene polymorphism affects the susceptibility to olanzapine | affects response to substance | 20547447
|
C076029 |
olanzapine |
MTHFR protein affects the susceptibility to olanzapine | affects response to substance | 20547447
|
C006253 |
pirinixic acid |
pirinixic acid results in increased expression of MTHFR mRNA | increases expression | 18301758
|
D020849 |
Raloxifene |
Raloxifene results in decreased expression of MTHFR mRNA | decreases expression | 15849065
|
C017947 |
sodium arsenite |
sodium arsenite results in decreased expression of MTHFR protein | decreases expression | 19766132
|
D013629 |
Tamoxifen |
Tamoxifen results in decreased expression of MTHFR mRNA | decreases expression | 15849065
|
D012256 |
Riboflavin |
MTHFR gene polymorphism affects the susceptibility to Riboflavin | affects response to substance | 17303386
|
Disease ID |
Disease Name |
Direct Evidence |
Inference Chemical Name |
Inference Score |
Publication |
---|
MESH:D000008 |
Abdominal Neoplasms |
|
Tamoxifen |
4.47 | 14745880 |
MESH:D000014 |
Abnormalities, Drug-Induced |
|
Methotrexate |
4.16 | 12039119 |
MESH:D000138 |
Acidosis |
|
Ammonium Chloride |
3.47 | 18287403 |
MESH:D058186 |
Acute Kidney Injury |
|
Folic Acid |
4.25 | 16595132 16316344 17003819 |
MESH:D055371 |
Acute Lung Injury |
|
pirinixic acid |
3.03 | 18653653 |
MESH:D000230 |
Adenocarcinoma |
|
Fluorouracil |
2.41 | 17638652 |
MESH:D000236 |
Adenoma |
|
Folic Acid |
3.74 | 16963246 |
MESH:D018248 |
Adenoma, Liver Cell |
|
pirinixic acid |
3.40 | 16434500 |
MESH:D000310 |
Adrenal Gland Neoplasms |
|
sodium arsenite |
4.62 | 15276417 |
MESH:D018246 |
Adrenocortical Adenoma |
|
Arsenic |
13.52 | 17306315 |
MESH:D018246 |
Adrenocortical Adenoma |
|
sodium arsenite |
13.52 | 16712894 17306315 |
MESH:D000380 |
Agranulocytosis |
|
Clozapine |
4.97 | 14617031 16160616 12649775 |
MESH:D000419 |
Albuminuria |
|
Raloxifene |
4.51 | 17308373 17451421 |
MESH:D000544 |
Alzheimer Disease |
marker/mechanism |
|
| 17192785 |
MESH:D000544 |
Alzheimer Disease |
|
Folic Acid |
4.53 | 17116317 |
MESH:D000544 |
Alzheimer Disease |
|
Raloxifene |
4.53 | 15800139 |
MESH:D000740 |
Anemia |
|
Fluorouracil |
3.63 | 15504547 16511603 17963324 |
MESH:D020261 |
Arsenic Poisoning |
|
Arsenic |
2.84 | 16251483 12569548 18414634 16835338 |
MESH:D001172 |
Arthritis, Rheumatoid |
|
Methotrexate |
3.08 | 17286800 |
MESH:D050197 |
Atherosclerosis |
|
Arsenic |
3.20 | 12928151 19371607 |
MESH:D001321 |
Autistic Disorder |
marker/mechanism |
|
| 19267885 |
MESH:D001321 |
Autistic Disorder |
|
5-methyltetrahydrofolate |
3.63 | 18461502 |
MESH:D001321 |
Autistic Disorder |
|
Folic Acid |
3.63 | 21388746 |
MESH:D001321 |
Autistic Disorder |
|
Homocysteine |
3.63 | 16297937 20468076 |
MESH:D001321 |
Autistic Disorder |
|
Methionine |
3.63 | 19267885 16917939 19056591 |
MESH:D001321 |
Autistic Disorder |
|
olanzapine |
3.63 | 18685284 17069543 |
MESH:D001714 |
Bipolar Disorder |
marker/mechanism |
|
| 17074966 |
MESH:D001778 |
Blood Coagulation Disorders |
|
pirinixic acid |
3.06 | 19483382 |
MESH:D025861 |
Blood Coagulation Disorders, Inherited |
marker/mechanism |
|
| 17493413 |
MESH:D001930 |
Brain Injuries |
|
Raloxifene |
4.39 | 16580743 |
MESH:D001943 |
Breast Neoplasms |
marker/mechanism |
|
| 16777985 17595805 |
MESH:D001943 |
Breast Neoplasms |
|
Fluorouracil |
2.35 | 16595493 15136595 16557594 19217205 16110121 18608205 18357371 |
MESH:D001943 |
Breast Neoplasms |
|
Folic Acid |
2.35 | 16777985 |
MESH:D001943 |
Breast Neoplasms |
|
Methotrexate |
2.35 | 16978400 |
MESH:D001943 |
Breast Neoplasms |
|
Raloxifene |
2.35 | 15758505 17440819 15775269 17952589 17893378 17595753 15572757 17242785 17049068 16912660 17261762 16837676 |
MESH:D001943 |
Breast Neoplasms |
|
Tamoxifen |
2.35 | 20065188 15565566 20859285 15668708 21152245 20005174 18815881 11161223 17261762 20135344 19103187 19155303 18997820 19115204 18821012 19289846 19011961 19084267 17440819 19221464 19066611 20544844 19487384 16202921 17893378 18629630 19059307 19189210 19288272 18984771 17049068 18855134 16818667 18425577 16873071 19142967 19244106 19189212 16273361 18351453 21138602 17242785 19200415 20390343 19410462 |
MESH:D002276 |
Carcinoid Tumor |
|
Fluorouracil |
4.59 | 16051944 |
MESH:D002277 |
Carcinoma |
|
Fluorouracil |
3.49 | 17121937 |
MESH:D002280 |
Carcinoma, Basal Cell |
|
Arsenic |
3.54 | 15504454 17687452 |
MESH:D018270 |
Carcinoma, Ductal, Breast |
|
Tamoxifen |
4.42 | 19066611 |
MESH:D006528 |
Carcinoma, Hepatocellular |
|
Arsenic |
6.50 | 17306315 16507464 |
MESH:D006528 |
Carcinoma, Hepatocellular |
|
Fluorouracil |
6.50 | 16799960 17045692 18930000 16332177 17971768 17088986 |
MESH:D006528 |
Carcinoma, Hepatocellular |
|
sodium arsenite |
6.50 | 16507464 17306315 15276417 |
MESH:D006528 |
Carcinoma, Hepatocellular |
|
Tamoxifen |
6.50 | 16924424 |
MESH:D002292 |
Carcinoma, Renal Cell |
|
Fluorouracil |
2.98 | 18695887 |
MESH:D002294 |
Carcinoma, Squamous Cell |
|
Arsenic |
7.47 | 17687452 18922899 15504454 |
MESH:D002294 |
Carcinoma, Squamous Cell |
|
Fluorouracil |
7.47 | 18986760 16280240 17066447 16757204 |
MESH:D002294 |
Carcinoma, Squamous Cell |
|
sodium arsenite |
7.47 | 18572023 |
MESH:D002295 |
Carcinoma, Transitional Cell |
|
Arsenic |
15.46 | 18640142 |
MESH:D002295 |
Carcinoma, Transitional Cell |
|
Raloxifene |
15.46 | 17572228 |
MESH:D002295 |
Carcinoma, Transitional Cell |
|
Tamoxifen |
15.46 | 17572228 |
MESH:D002318 |
Cardiovascular Diseases |
marker/mechanism |
|
| 16958597 |
MESH:D002318 |
Cardiovascular Diseases |
|
Arsenic |
11.98 | 19152805 15738583 17938729 |
MESH:D002318 |
Cardiovascular Diseases |
|
Folic Acid |
11.98 | 16755160 |
MESH:D002318 |
Cardiovascular Diseases |
|
Raloxifene |
11.98 | 15775269 |
MESH:D002340 |
Carotid Artery Diseases |
|
Arsenic |
4.23 | 16973168 18022660 |
MESH:D002389 |
Catatonia |
|
olanzapine |
6.17 | 18071103 16772815 |
MESH:D002471 |
Cell Transformation, Neoplastic |
|
Cytarabine |
7.09 | 8243401 |
MESH:D002471 |
Cell Transformation, Neoplastic |
|
sodium arsenite |
7.09 | 19524636 20056578 |
MESH:D018290 |
Cervical Intraepithelial Neoplasia |
marker/mechanism |
|
| 17303386 |
MESH:D002659 |
Child Development Disorders, Pervasive |
|
Methionine |
4.29 | 19267885 |
MESH:D015362 |
Child Nutrition Disorders |
|
Riboflavin |
6.86 | 16153327 |
MESH:D002779 |
Cholestasis |
|
pirinixic acid |
2.76 | 19176532 |
MESH:D002971 |
Cleft Lip |
marker/mechanism |
|
| 16470725 |
MESH:D002971 |
Cleft Lip |
|
Folic Acid |
3.93 | 21254359 |
MESH:D002972 |
Cleft Palate |
|
Folic Acid |
3.53 | 21254359 8946559 |
MESH:D003025 |
Clubfoot |
marker/mechanism |
|
| 16936070 |
MESH:D003072 |
Cognition Disorders |
|
Clozapine |
11.39 | 17123785 |
MESH:D003072 |
Cognition Disorders |
|
Raloxifene |
11.39 | 15800139 |
MESH:D003110 |
Colonic Neoplasms |
marker/mechanism |
|
| 16284371 |
MESH:D003110 |
Colonic Neoplasms |
|
Fluorouracil |
2.22 | 18772588 17018589 15001691 17287894 16510598 17016597 17725105 17172411 17169374 16340194 |
MESH:D015179 |
Colorectal Neoplasms |
marker/mechanism |
|
| 15608557 17047490 18676755 16512993 16985020 17087956 17245555 17350979 |
MESH:D015179 |
Colorectal Neoplasms |
|
Floxuridine |
4.96 | 15040806 |
MESH:D015179 |
Colorectal Neoplasms |
|
Fluorouracil |
4.96 | 20501625 18448328 17695437 14970324 17401013 17454858 16524972 15289873 16282729 18288408 18802399 17255274 16331619 18509181 15148649 16303861 17016601 17594712 18949393 16391804 18383874 17094418 |
MESH:D015179 |
Colorectal Neoplasms |
|
Folic Acid |
4.96 | 17245555 17116713 17087956 16963246 16985020 |
MESH:D015179 |
Colorectal Neoplasms |
|
Leucovorin |
4.96 | 17255274 16303861 17594712 17454858 20501625 17401013 |
MESH:D003324 |
Coronary Artery Disease |
|
Homocysteine |
3.72 | 16379339 |
MESH:D023903 |
Coronary Restenosis |
marker/mechanism |
|
| 16489563 |
MESH:D019465 |
Craniofacial Abnormalities |
|
Leucovorin |
3.58 | 16925845 |
MESH:D019465 |
Craniofacial Abnormalities |
|
Methotrexate |
3.58 | 12039119 9562676 |
MESH:D003550 |
Cystic Fibrosis |
|
Methotrexate |
4.16 | 19747007 |
MESH:D007644 |
Darier Disease |
|
Fluorouracil |
4.71 | 16733453 |
MESH:D003711 |
Demyelinating Diseases |
|
Tamoxifen |
4.28 | 19031437 |
MESH:D003866 |
Depressive Disorder |
marker/mechanism |
|
| 17074966 |
MESH:D003865 |
Depressive Disorder, Major |
|
Raloxifene |
4.08 | 17474826 |
MESH:D003876 |
Dermatitis, Atopic |
|
pirinixic acid |
2.38 | 18249437 |
MESH:D003882 |
Dermatomyositis |
|
Methotrexate |
5.04 | 20191521 |
MESH:D002658 |
Developmental Disabilities |
|
olanzapine |
4.63 | 17069543 |
MESH:D003924 |
Diabetes Mellitus, Type 2 |
|
Clozapine |
4.97 | 16402076 |
MESH:D003924 |
Diabetes Mellitus, Type 2 |
|
Folic Acid |
4.97 | 16886840 |
MESH:D003925 |
Diabetic Angiopathies |
marker/mechanism |
|
| 16681562 |
MESH:D003928 |
Diabetic Nephropathies |
|
Raloxifene |
8.78 | 17451421 15920148 17308373 |
MESH:D003928 |
Diabetic Nephropathies |
|
Tamoxifen |
8.78 | 19279558 |
MESH:D006970 |
Disorders of Excessive Somnolence |
|
Clozapine |
5.47 | 15331141 |
MESH:D004314 |
Down Syndrome |
marker/mechanism |
|
| 16353284 16489479 16845273 17431899 |
MESH:D003875 |
Drug Eruptions |
marker/mechanism |
|
| 14723717 |
MESH:D050171 |
Dyslipidemias |
|
Clozapine |
4.12 | 16402076 |
MESH:D004487 |
Edema |
|
pirinixic acid |
6.62 | 12083418 |
MESH:D004487 |
Edema |
|
Raloxifene |
6.62 | 15860553 |
MESH:D004681 |
Encephalomyelitis, Autoimmune, Experimental |
|
Raloxifene |
8.96 | 15845917 |
MESH:D004681 |
Encephalomyelitis, Autoimmune, Experimental |
|
Tamoxifen |
8.96 | 19031437 |
MESH:D016889 |
Endometrial Neoplasms |
marker/mechanism |
|
| 17301261 |
MESH:D016889 |
Endometrial Neoplasms |
|
Folic Acid |
7.58 | 17301261 |
MESH:D016889 |
Endometrial Neoplasms |
|
Tamoxifen |
7.58 | 17893378 16202921 19155303 20544844 |
MESH:D004938 |
Esophageal Neoplasms |
|
Fluorouracil |
2.43 | 17638652 16481741 16785472 16337965 15173087 |
MESH:D017889 |
Exfoliation Syndrome |
|
Folic Acid |
13.10 | 16504073 |
MESH:D017889 |
Exfoliation Syndrome |
|
Homocysteine |
13.10 | 16504073 |
MESH:D005234 |
Fatty Liver |
|
pirinixic acid |
12.67 | 20131406 19236843 |
MESH:D005234 |
Fatty Liver |
|
Raloxifene |
12.67 | 17473493 |
MESH:D005234 |
Fatty Liver |
|
Tamoxifen |
12.67 | 14986274 19224547 |
MESH:D052776 |
Female Urogenital Diseases |
|
Tamoxifen |
3.18 | 16709447 |
MESH:D018221 |
Fibromatosis, Abdominal |
|
Tamoxifen |
4.44 | 14745880 |
MESH:D018222 |
Fibromatosis, Aggressive |
|
Tamoxifen |
4.10 | 19069698 |
MESH:D005534 |
Foot Diseases |
|
Arsenic |
5.48 | 6392382 |
MESH:D005756 |
Gastritis |
|
Folic Acid |
5.01 | 17171786 |
MESH:D005833 |
Genital Neoplasms, Female |
|
sodium arsenite |
4.59 | 16452187 |
MESH:D005901 |
Glaucoma |
|
Folic Acid |
11.57 | 16504073 |
MESH:D005901 |
Glaucoma |
|
Homocysteine |
11.57 | 16504073 |
MESH:D005910 |
Glioma |
|
Fluorouracil |
2.83 | 16145905 |
MESH:D006086 |
Graft vs Host Disease |
marker/mechanism |
|
| 16518429 |
MESH:D006086 |
Graft vs Host Disease |
|
Methotrexate |
5.06 | 16518429 |
MESH:D006258 |
Head and Neck Neoplasms |
|
Fluorouracil |
3.33 | 15162350 15102660 18337622 |
MESH:D003639 |
Hearing Loss, Sudden |
marker/mechanism |
|
| 16275406 |
MESH:D006330 |
Heart Defects, Congenital |
marker/mechanism |
|
| 16524890 |
MESH:D006330 |
Heart Defects, Congenital |
|
Folic Acid |
7.33 | 17286298 16524890 |
MESH:D006330 |
Heart Defects, Congenital |
|
Homocysteine |
7.33 | 19638421 |
MESH:D006331 |
Heart Diseases |
|
Raloxifene |
3.47 | 11110106 |
MESH:D006333 |
Heart Failure |
|
pirinixic acid |
2.48 | 20558911 |
MESH:D006529 |
Hepatomegaly |
|
pirinixic acid |
2.91 | 18467677 16221962 19772884 19176532 |
MESH:D006679 |
HIV Seropositivity |
|
Folic Acid |
5.41 | 17209195 |
MESH:D006689 |
Hodgkin Disease |
|
Cytarabine |
7.60 | 16200630 |
MESH:D006689 |
Hodgkin Disease |
|
sodium arsenite |
7.60 | 12676792 |
MESH:D006712 |
Homocystinuria |
|
5-methyltetrahydrofolate |
6.74 | 17413090 |
OMIM:236250 |
HOMOCYSTINURIA DUE TO DEFICIENCY OF N(5,10)-METHYLENETETRAHYDROFOLATE REDUCTASE ACTIVITY |
marker/mechanism |
|
| |
MESH:D006943 |
Hyperglycemia |
|
pirinixic acid |
3.10 | 20558911 |
MESH:D020138 |
Hyperhomocysteinemia |
marker/mechanism |
|
| 19204075 10459572 18234410 16317120 16397167 16411416 16575899 |
MESH:D020138 |
Hyperhomocysteinemia |
|
Folic Acid |
9.58 | 16865747 16395265 16397167 16755160 16433478 |
MESH:D020138 |
Hyperhomocysteinemia |
|
Homocysteine |
9.58 | 17292331 18234410 17369066 |
MESH:D017488 |
Hyperkeratosis, Epidermolytic |
|
Arsenic |
4.38 | 17050553 |
MESH:D006948 |
Hyperkinesis |
|
Clozapine |
4.82 | 16046005 |
MESH:D006963 |
Hyperphagia |
|
olanzapine |
6.14 | 17933447 |
MESH:D006967 |
Hypersensitivity |
marker/mechanism |
|
| 16766537 |
MESH:D006973 |
Hypertension |
|
Arsenic |
5.47 | 16076760 9931084 11953799 |
MESH:D006973 |
Hypertension |
|
Raloxifene |
5.47 | 15787275 17577099 |
MESH:D006987 |
Hypesthesia |
|
Arsenic |
5.48 | 16093927 |
MESH:D007247 |
Infertility, Female |
marker/mechanism |
|
| 16679164 |
MESH:D007248 |
Infertility, Male |
marker/mechanism |
|
| 16861746 |
MESH:D007248 |
Infertility, Male |
|
sodium arsenite |
2.93 | 15346721 12646999 |
MESH:D007249 |
Inflammation |
|
Tamoxifen |
2.31 | 19457130 |
MESH:D007333 |
Insulin Resistance |
|
pirinixic acid |
2.57 | 16306350 |
MESH:D007642 |
Keratosis |
|
Arsenic |
4.90 | 16930632 12749816 |
MESH:D007674 |
Kidney Diseases |
|
sodium arsenite |
2.75 | 20008137 |
MESH:D007680 |
Kidney Neoplasms |
|
Fluorouracil |
7.26 | 16985049 |
MESH:D007680 |
Kidney Neoplasms |
|
Tamoxifen |
7.26 | 18625569 |
MESH:D007805 |
Language Development Disorders |
|
Methotrexate |
5.02 | 9562676 |
MESH:D007889 |
Leiomyoma |
|
Raloxifene |
4.41 | 16973256 |
MESH:D015451 |
Leukemia, Lymphocytic, Chronic, B-Cell |
marker/mechanism |
|
| 16706930 |
MESH:D015473 |
Leukemia, Promyelocytic, Acute |
|
Arsenic |
3.49 | 17339181 |
MESH:D008064 |
Lipidoses |
|
Clozapine |
7.87 | 17567588 |
MESH:D008064 |
Lipidoses |
|
Tamoxifen |
7.87 | 17567588 15342952 |
MESH:D008103 |
Liver Cirrhosis |
|
Methotrexate |
3.65 | 14986274 |
MESH:D008106 |
Liver Cirrhosis, Experimental |
|
Methionine |
3.63 | 15158331 |
MESH:D008106 |
Liver Cirrhosis, Experimental |
|
pirinixic acid |
3.63 | 15474484 |
MESH:D008106 |
Liver Cirrhosis, Experimental |
|
Tamoxifen |
3.63 | 18564211 |
MESH:D008107 |
Liver Diseases |
marker/mechanism |
|
| 16877991 |
MESH:D008107 |
Liver Diseases |
|
Arsenic |
4.51 | 11134558 |
MESH:D008107 |
Liver Diseases |
|
Folic Acid |
4.51 | 16877991 |
MESH:D008113 |
Liver Neoplasms |
|
Arsenic |
13.90 | 16368122 |
MESH:D008113 |
Liver Neoplasms |
|
Fluorouracil |
13.90 | 17045692 18383874 15113037 16603448 |
MESH:D008113 |
Liver Neoplasms |
|
pirinixic acid |
13.90 | 15890375 20007298 16377806 |
MESH:D008113 |
Liver Neoplasms |
|
sodium arsenite |
13.90 | 16712894 15276417 |
MESH:D008113 |
Liver Neoplasms |
|
Tamoxifen |
13.90 | 16684651 |
MESH:D008133 |
Long QT Syndrome |
|
olanzapine |
4.66 | 20210726 |
MESH:D008171 |
Lung Diseases |
|
sodium arsenite |
3.11 | 19095001 |
MESH:D017563 |
Lung Diseases, Interstitial |
|
Methotrexate |
4.94 | 18516814 |
MESH:D008175 |
Lung Neoplasms |
marker/mechanism |
|
| 17389614 |
MESH:D008175 |
Lung Neoplasms |
|
Arsenic |
4.81 | 17306315 17976673 19168569 |
MESH:D008175 |
Lung Neoplasms |
|
Fluorouracil |
4.81 | 15246190 |
MESH:D008175 |
Lung Neoplasms |
|
sodium arsenite |
4.81 | 17306315 17077188 16712894 15276417 19931552 |
MESH:D008175 |
Lung Neoplasms |
|
Tamoxifen |
4.81 | 18625569 |
MESH:D008178 |
Lupus Erythematosus, Cutaneous |
|
Fluorouracil |
4.71 | 15086387 |
MESH:D008180 |
Lupus Erythematosus, Systemic |
|
Folic Acid |
3.31 | 17718048 |
MESH:D008223 |
Lymphoma |
marker/mechanism |
|
| 16799656 |
MESH:D008223 |
Lymphoma |
|
Methotrexate |
3.89 | 17352296 |
MESH:D008224 |
Lymphoma, Follicular |
marker/mechanism |
|
| 16410450 |
MESH:D008228 |
Lymphoma, Non-Hodgkin |
marker/mechanism |
|
| 17488658 |
MESH:D044342 |
Malnutrition |
marker/mechanism |
|
| 16709328 |
MESH:D015674 |
Mammary Neoplasms, Animal |
|
Tamoxifen |
3.67 | 19428831 |
MESH:D008325 |
Mammary Neoplasms, Experimental |
|
Tamoxifen |
2.57 | 11731420 19196722 14580682 19196723 16827153 |
MESH:D020149 |
Manganese Poisoning |
|
Tamoxifen |
4.47 | 19453300 |
MESH:D019767 |
Maxillofacial Abnormalities |
marker/mechanism |
|
| 16832597 |
MESH:D019767 |
Maxillofacial Abnormalities |
|
Folic Acid |
5.61 | 16832597 |
MESH:D008545 |
Melanoma |
|
sodium arsenite |
3.27 | 19082730 16487513 |
MESH:D008545 |
Melanoma |
|
Tamoxifen |
3.27 | 12393984 19393235 |
MESH:D018328 |
Melanoma, Amelanotic |
|
Tamoxifen |
4.10 | 15990972 |
MESH:D008591 |
Meningomyelocele |
marker/mechanism |
|
| 16602021 |
MESH:D008591 |
Meningomyelocele |
|
Homocysteine |
5.45 | 16602021 |
MESH:D001523 |
Mental Disorders |
|
Clozapine |
8.31 | 16856516 |
MESH:D001523 |
Mental Disorders |
|
olanzapine |
8.31 | 16856516 |
MESH:D008659 |
Metabolic Diseases |
|
olanzapine |
5.31 | 19142110 |
MESH:D024821 |
Metabolic Syndrome X |
|
Clozapine |
4.34 | 19142101 |
MESH:D053842 |
Microsatellite Instability |
marker/mechanism |
|
| 17350979 |
MESH:D017566 |
Microvascular Angina |
marker/mechanism |
|
| 17491230 |
MESH:D008881 |
Migraine Disorders |
|
Riboflavin |
5.53 | 18803445 |
MESH:D018200 |
Mixed Tumor, Mullerian |
|
Raloxifene |
5.47 | 15863610 |
MESH:D009062 |
Mouth Neoplasms |
|
Fluorouracil |
3.56 | 18986760 16757204 |
MESH:D052016 |
Mucositis |
marker/mechanism |
|
| 17488658 |
MESH:D052016 |
Mucositis |
|
Methotrexate |
5.19 | 17488658 |
MESH:D009101 |
Multiple Myeloma |
|
Raloxifene |
3.37 | 16497877 |
MESH:D009135 |
Muscular Diseases |
|
pirinixic acid |
3.42 | 16239165 |
MESH:D009203 |
Myocardial Infarction |
|
Homocysteine |
5.87 | 17412321 |
MESH:D009203 |
Myocardial Infarction |
|
pirinixic acid |
5.87 | 19151258 |
MESH:D017202 |
Myocardial Ischemia |
|
Arsenic |
3.91 | 15371236 |
MESH:D015428 |
Myocardial Reperfusion Injury |
|
pirinixic acid |
2.88 | 16411023 |
MESH:D009232 |
Myxoma |
|
Raloxifene |
5.47 | 16343187 |
MESH:D009336 |
Necrosis |
marker/mechanism |
|
| 14723717 |
MESH:D009362 |
Neoplasm Metastasis |
marker/mechanism |
|
| 17704422 |
MESH:D009362 |
Neoplasm Metastasis |
|
Tamoxifen |
2.51 | 19393235 |
MESH:D009364 |
Neoplasm Recurrence, Local |
|
Tamoxifen |
2.49 | 19410462 |
MESH:D009369 |
Neoplasms |
|
Fluorouracil |
8.01 | 18600527 18239605 16928823 |
MESH:D009369 |
Neoplasms |
|
pirinixic acid |
8.01 | 17405874 |
MESH:D009369 |
Neoplasms |
|
sodium arsenite |
8.01 | 11559025 |
MESH:D009374 |
Neoplasms, Experimental |
|
sodium arsenite |
3.58 | 20056578 |
MESH:D009376 |
Neoplasms, Hormone-Dependent |
|
Tamoxifen |
3.92 | 19196722 19200415 19189210 |
MESH:D009436 |
Neural Tube Defects |
|
5-methyltetrahydrofolate |
17.03 | 17413090 |
MESH:D009436 |
Neural Tube Defects |
|
Arsenic |
17.03 | 16620997 |
MESH:D009436 |
Neural Tube Defects |
|
Folic Acid |
17.03 | 17438019 |
MESH:D009436 |
Neural Tube Defects |
|
sodium arsenite |
17.03 | 12854658 |
OMIM:601634 |
NEURAL TUBE DEFECTS, FOLATE-SENSITIVE |
marker/mechanism |
|
| |
MESH:D020078 |
Neurogenic Inflammation |
|
Arsenic |
4.29 | 17056641 |
MESH:D020258 |
Neurotoxicity Syndromes |
|
Fluorouracil |
3.38 | 16436463 |
MESH:D009503 |
Neutropenia |
|
Folic Acid |
4.42 | 16322990 |
MESH:D009765 |
Obesity |
|
Clozapine |
7.54 | 18515891 19142110 |
MESH:D009765 |
Obesity |
|
olanzapine |
7.54 | 18515891 |
MESH:D009765 |
Obesity |
|
pirinixic acid |
7.54 | 20558911 |
OMIM:119530 |
OROFACIAL CLEFT 1 |
marker/mechanism |
|
| |
MESH:D010024 |
Osteoporosis |
|
Raloxifene |
3.34 | 19059307 17882678 15775268 |
MESH:D015663 |
Osteoporosis, Postmenopausal |
|
Raloxifene |
4.14 | 15758505 17823083 15579764 17893378 |
MESH:D010051 |
Ovarian Neoplasms |
|
Arsenic |
4.94 | 17306315 |
MESH:D010051 |
Ovarian Neoplasms |
|
sodium arsenite |
4.94 | 15276417 17306315 |
MESH:D010190 |
Pancreatic Neoplasms |
|
Fluorouracil |
2.63 | 19003803 16929163 15113037 16500647 |
MESH:D010300 |
Parkinson Disease |
|
Homocysteine |
3.54 | 16275827 |
MESH:D010523 |
Peripheral Nervous System Diseases |
|
Arsenic |
4.09 | 16093927 |
MESH:D016491 |
Peripheral Vascular Diseases |
|
Arsenic |
4.90 | 6392382 15371236 16905509 |
MESH:D054198 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
marker/mechanism |
|
| 16706930 |
MESH:D054198 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
|
Cytarabine |
4.39 | 21297632 |
MESH:D011471 |
Prostatic Neoplasms |
marker/mechanism |
|
| 17967524 |
MESH:D011471 |
Prostatic Neoplasms |
|
Arsenic |
1.88 | 16140617 |
MESH:D011471 |
Prostatic Neoplasms |
|
Fluorouracil |
1.88 | 18626508 19082440 |
MESH:D011471 |
Prostatic Neoplasms |
|
Raloxifene |
1.88 | 16536755 15731164 16220300 |
MESH:D011471 |
Prostatic Neoplasms |
|
sodium arsenite |
1.88 | 16039940 |
MESH:D011471 |
Prostatic Neoplasms |
|
Tamoxifen |
1.88 | 15067354 |
MESH:D011507 |
Proteinuria |
|
Arsenic |
3.92 | 21343184 |
MESH:D011565 |
Psoriasis |
|
Methotrexate |
3.40 | 17410198 |
MESH:D011595 |
Psychomotor Agitation |
|
olanzapine |
5.50 | 18685284 |
MESH:D011618 |
Psychotic Disorders |
|
Clozapine |
4.12 | 15331141 |
MESH:D011693 |
Purpura |
|
Raloxifene |
5.47 | 15770314 |
MESH:D012004 |
Rectal Neoplasms |
|
Fluorouracil |
3.93 | 18286688 18722050 16160472 15538739 |
MESH:D051437 |
Renal Insufficiency |
|
Folic Acid |
10.41 | 15728788 |
MESH:D051437 |
Renal Insufficiency |
|
Methotrexate |
10.41 | 17352296 |
MESH:D015427 |
Reperfusion Injury |
|
Leucovorin |
6.91 | 17295595 |
MESH:D015427 |
Reperfusion Injury |
|
pirinixic acid |
6.91 | 19058328 |
MESH:D012559 |
Schizophrenia |
marker/mechanism |
|
| 18583979 16641680 17074966 |
MESH:D012559 |
Schizophrenia |
|
Clozapine |
10.52 | 11763009 20168265 20452607 20521320 20521326 16141801 17726453 18855531 20107430 11151749 20580759 17123785 18806925 17667964 19369910 |
MESH:D012559 |
Schizophrenia |
|
Folic Acid |
10.52 | 16641680 |
MESH:D012559 |
Schizophrenia |
|
Homocysteine |
10.52 | 16641680 |
MESH:D012559 |
Schizophrenia |
|
Methionine |
10.52 | 15737665 |
MESH:D012559 |
Schizophrenia |
|
olanzapine |
10.52 | 20107430 20521326 17726453 |
MESH:D012851 |
Sinus Thrombosis, Intracranial |
marker/mechanism |
|
| 18941937 |
MESH:D012871 |
Skin Diseases |
marker/mechanism |
|
| 17548696 |
MESH:D012871 |
Skin Diseases |
|
Arsenic |
8.27 | 16353154 6392382 17548696 16702368 16759981 19834688 15952646 17050553 17453740 18709164 17938729 |
MESH:D012871 |
Skin Diseases |
|
Folic Acid |
8.27 | 18709164 |
MESH:D012871 |
Skin Diseases |
|
Riboflavin |
8.27 | 18709164 |
MESH:D012878 |
Skin Neoplasms |
|
Arsenic |
5.81 | 17976673 17050553 17029826 19538983 15504454 16251483 |
MESH:D012878 |
Skin Neoplasms |
|
sodium arsenite |
5.81 | 19524636 18572023 |
MESH:D013088 |
Spermatocele |
|
Tamoxifen |
4.21 | 16709447 |
MESH:D013118 |
Spinal Cord Diseases |
marker/mechanism |
|
| 16361298 |
MESH:D013118 |
Spinal Cord Diseases |
|
Folic Acid |
5.41 | 16361298 |
MESH:D013119 |
Spinal Cord Injuries |
|
Tamoxifen |
3.95 | 19457130 |
MESH:D016135 |
Spinal Dysraphism |
|
sodium arsenite |
3.73 | 12854658 |
MESH:D013274 |
Stomach Neoplasms |
marker/mechanism |
|
| 18505952 |
MESH:D013274 |
Stomach Neoplasms |
|
Fluorouracil |
2.82 | 19084572 16951190 17522103 18396642 15786421 16424979 17498489 18567086 17172411 19015929 |
MESH:D013274 |
Stomach Neoplasms |
|
Folic Acid |
2.82 | 17171786 |
MESH:D020521 |
Stroke |
marker/mechanism |
|
| 16681562 |
MESH:D020521 |
Stroke |
|
Folic Acid |
14.42 | 16517955 |
MESH:D020521 |
Stroke |
|
Raloxifene |
14.42 | 16837676 |
MESH:D020521 |
Stroke |
|
Riboflavin |
14.42 | 16517955 |
MESH:D013576 |
Syndactyly |
|
Methotrexate |
4.95 | 9562676 |
MESH:D017180 |
Tachycardia, Ventricular |
|
olanzapine |
5.25 | 20210726 |
MESH:D019851 |
Thrombophilia |
marker/mechanism |
|
| 17493413 |
MESH:D013971 |
Thyrotoxicosis |
marker/mechanism |
|
| 18941937 |
MESH:D013978 |
Tibial Fractures |
|
Raloxifene |
5.13 | 19048282 |
MESH:D014062 |
Tongue Neoplasms |
|
Fluorouracil |
3.91 | 16280240 |
MESH:D001749 |
Urinary Bladder Neoplasms |
|
Arsenic |
11.69 | 19429237 11144890 18640142 19322015 15987713 17976673 17306315 |
MESH:D001749 |
Urinary Bladder Neoplasms |
|
Raloxifene |
11.69 | 17572228 |
MESH:D001749 |
Urinary Bladder Neoplasms |
|
sodium arsenite |
11.69 | 17306315 11723127 16452187 16712894 |
MESH:D001749 |
Urinary Bladder Neoplasms |
|
Tamoxifen |
11.69 | 17572228 8653321 16712894 |
MESH:D002583 |
Uterine Cervical Neoplasms |
marker/mechanism |
|
| 17303386 |
MESH:D002583 |
Uterine Cervical Neoplasms |
|
Fluorouracil |
9.22 | 16803524 |
MESH:D002583 |
Uterine Cervical Neoplasms |
|
sodium arsenite |
9.22 | 11813266 |
MESH:D014652 |
Vascular Diseases |
|
Arsenic |
11.56 | 17056641 |
MESH:D014652 |
Vascular Diseases |
|
sodium arsenite |
11.56 | 17056641 |
MESH:D054556 |
Venous Thromboembolism |
|
Raloxifene |
5.13 | 16837676 |
MESH:D014846 |
Vulvar Neoplasms |
|
Raloxifene |
5.47 | 16343187 |
MESH:D015430 |
Weight Gain |
|
Clozapine |
10.09 | 20521320 20564506 16141801 17502770 16402076 20107430 |
MESH:D015430 |
Weight Gain |
|
olanzapine |
10.09 | 19434072 17933447 20107430 |
MESH:D015431 |
Weight Loss |
|
Clozapine |
4.99 | 17933447 |